The Proteus Syndrome market is entering a pivotal decade, driven by increasing disease recognition, improving diagnostic techniques, development of genetic testing techniques and other innovative ...

AstraZeneca and its partner Daiichi Sankyo have won approval from U.S. regulators for their precision drug Datroway to treat a type of lung cancer, marking the first approval of the therapy in this ...

Laura McMullin, General Manager, Daiichi Sankyo UK, has been appointed Vice President of the ABPI to support UK life sciences ...

Daiichi Sankyo (TSE: 4568) and Merck (known as MSD outside of the United States and Canada) (NYSE: MRK) have entered into a global development and com ...

MADRID—Daiichi Sankyo and ADC partner AstraZeneca finally have some clarity on the deaths that occurred in a pair of phase 3 studies for their Enhertu follow up Dato-DXd.

An AstraZeneca and Daiichi Sankyo cancer drug achieved one of the main goals of a Phase 3 study in non-small cell lung cancer. But patient deaths were also reported in the study, and the companies ...

Daiichi Sankyo Co. plans to file for US approval of its novel lung cancer drug by the end of March after the medicine showed a benefit in patients with advanced disease.

Daiichi Sankyo and MSD's partnership, which began in October 2023, encompasses the co-development and commercialisation of patritumab deruxtecan (HER3-DXd), raludotatug deruxtecan (R-DXd), and I-DXd.

Today, Daiichi Sankyo Europe GmbH, the European headquarter organisation of the Japanese pharmaceutical company Daiichi Sankyo Co., Ltd., announced th Change in Leadership at Daiichi Sankyo Europe ...

Daiichi Sankyo has stepped up its efforts to bring a Japanese COVID-19 vaccine to patients, starting a new clinical trial of its mRNA-based candidate DS-5670 that focuses on its use as a booster dose.

On top of being Enhertu’s first foray into DTC marketing, the campaign represents “the first DTC that we’ve developed at Daiichi Sankyo for any of our oncology products," Dan Switzer, head ...

The Association of the British Pharmaceutical Industry (ABPI) has appointed Laura McMullin as vice president of the trade ...